RESUMO
BACKGROUND: Nusinersen is the first drug for precise targeted therapy of spinal muscular atrophy, a rare disease that occurs in one of 10,000 to 20,000 live births. Therefore, thorough and comprehensive reports on the safety of nusinersen in large, real-world populations are necessary. This study aimed to mine the adverse event (AE) signals related to nusinersen through the Food and Drug Administration Adverse Event Reporting System (FAERS) database. METHODS: We extracted reports of AEs with nusinersen as the primary suspect from FAERS between December 2016 and March 2023. Reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN) were used for AE signal detection. RESULTS: We extracted a total of 4807 suspected AE cases with nusinersen as the primary suspect from the FAERS database. Among them, 106 positive signals were obtained using the ROR and BCPNN. The highest frequency reported systemic organ class was general disorders and administration site conditions. Common clinical AEs of nusinersen were detected in the FAERS database, such as pneumonia, vomiting, back pain, headache, pyrexia, and post-lumbar puncture syndrome. In addition, we identified potential unexpected serious AEs through disproportionality analysis, including sepsis, seizure, epilepsy, brain injury, cardiorespiratory arrest, and cardiac arrest. CONCLUSIONS: Analyzing large amounts of real-world data from the FAERS database, we identified potential new AEs of nusinersen by disproportionate analysis. It is advantageous for health care professionals and pharmacists to concentrate on effectively managing high-risk AEs of nusinersen, improve medication levels in clinical settings, and uphold patient medication safety.
Assuntos
Sistemas de Notificação de Reações Adversas a Medicamentos , Oligonucleotídeos , Farmacovigilância , United States Food and Drug Administration , Humanos , Estados Unidos , Sistemas de Notificação de Reações Adversas a Medicamentos/estatística & dados numéricos , Oligonucleotídeos/efeitos adversos , Bases de Dados Factuais , Masculino , Feminino , Atrofia Muscular Espinal/tratamento farmacológico , Atrofia Muscular Espinal/induzido quimicamente , CriançaRESUMO
BACKGROUND: Spinal muscular atrophy (SMA) is a severe neuromuscular disorder, the phenotype of the disease is caused by the mutation of the SMN1 (survival motor neuron 1) gene which encodes for the SMN protein. Innovative treatments for SMA have become available and the first molecule approved is Nusinersen, an antisense oligonucleotide that increases the production of SMN protein. Nusinersen has been shown to be associated with a significant motor improvement and an increase of the event-free survival. For these reasons the aim of the present study is to assess if Nusinersen is able modify sleep architecture and microstructure and to improve sleep structure in these patients. METHODS: Sixteen patients affected by SMA1 were enrolled in the study (4 boys, 12 girls; median age 72.5 months, intelligence quotient range 24-84). All patients underwent complete nocturnal PSG before the start of the treatment trough intrathecal injections with Nusinersen (T0) and after the fifth infusion (day 180, T180). PSG recordings were visually scored and interpreted according to the indications of the American Academy of Sleep Medicine (AASM) and and microstructure by means of the Cyclic Alternating Pattern (CAP). RESULTS: After 6 months therapy we found a significantly reduced sleep latency and a significantly increased sleep efficiency. Regarding sleep microstructure parameters (CAP), we did not find any significant change after therapy however, it is worth mentioning that a moderate effect size was observed for the increase in CAP A3 index. CONCLUSIONS: We observed short-term effects of Nusinersen on sleep with an improvement in sleep efficiency and reduction in sleep onset latency; regarding sleep microstructure, a moderate effect size was found for the number of CAP A3 subtypes that slightly increased, possibly indicating a slightly higher arousability. This finding points at a probably overall better sleep pattern organization associated with the treatment, but they need to be confirmed by larger studies with patients treated earlier in life and for a longer period.
Assuntos
Atrofia Muscular Espinal , Atrofias Musculares Espinais da Infância , Masculino , Feminino , Humanos , Criança , Atrofias Musculares Espinais da Infância/tratamento farmacológico , Atrofias Musculares Espinais da Infância/complicações , Oligonucleotídeos/efeitos adversos , Sono/fisiologia , Atrofia Muscular Espinal/tratamento farmacológico , Atrofia Muscular Espinal/induzido quimicamente , Atrofia Muscular Espinal/complicaçõesRESUMO
Aim and Objectives: The objective of our retrospective study was to investigate the changes in pNFH levels in cerebrospinal fluid, which is a reliable marker of neuronal damage, after the loading dose of nusinersen in different types of spinal muscular atrophy. Materials and Methods: We analyzed the spinal muscular atrophy types, the number of copies of the SMN2 gene, and the progression of the motor status using specific motor function scales in a group of 38 patients with spinal muscular atrophy types 1, 2, and 3. Results: We found a significant inverse correlation between pNFH levels and patient age, progress on functional motor scales, and nusinersen administration. Our results also revealed that the neurofilament levels in the cerebrospinal fluid were higher in patients with 2 SMN2 copies than those with more than 2 copies, although the association was not statistically significant due to the abnormal distribution of the values. Conclusions: We identified several predictors of favorable evolution under nusinersen treatment, including spinal muscular atrophy type 1, children aged ≤ 30 months, and the presence of only 2 copies of SMN2. Our study provides important insights into the use of pNFH as a biomarker to monitor disease progression and responses to treatment in patients with spinal muscular atrophy.
Assuntos
Atrofia Muscular Espinal , Atrofias Musculares Espinais da Infância , Criança , Humanos , Estudos Retrospectivos , Atrofia Muscular Espinal/tratamento farmacológico , Atrofia Muscular Espinal/induzido quimicamente , Oligonucleotídeos/uso terapêutico , Atrofias Musculares Espinais da Infância/tratamento farmacológicoRESUMO
Gene therapies have greatly changed the outlook in spinal muscular atrophy (SMA), and this disorder provides a rare opportunity to study longitudinal biomarker changes correlated with reduced disease burden and improved clinical outcomes. Recent work suggests clinical response to correlate with declining cerebrospinal fluid (CSF) levels of the neurodegenerative marker neurofilament light chain (NfL) in children receiving serial anti-sense oligonucleotide therapy. However, change in CSF NfL levels is no longer a practical biomarker as more children undergo single-dose gene replacement therapy. Here we leverage serial CSF samples (median of 4 per child) collected in 13 children with SMA undergoing anti-sense oligonucleotide therapy to characterize the longitudinal profiles of NfL as well as inflammatory and neuronal proteins. In contrast to neurodegeneration in adults, we found NfL levels to first decrease following initiation of treatment but then increase upon further treatment and improved motor functions. We then examined additional CSF inflammatory and neuronal markers for linear association with motor function during SMA treatment. We identified longitudinal IL-8 levels to inversely correlate with motor functions determined by clinical examination (F(1, 47) = 12.903, p = 0.001) or electromyography in the abductor pollicis brevis muscle (p = 0.064). In keeping with this, lower baseline IL-8 levels were associated with better longitudinal outcomes, even though this difference diminished over 2 years in the younger group. We thus propose CSF IL-8 as a biomarker for baseline function and short-term treatment response in SMA, and a candidate biomarker for future treatment trials in other neurodegenerative disorders.
Assuntos
Terapia Genética , Interleucina-8 , Atrofia Muscular Espinal , Oligonucleotídeos Antissenso , Criança , Humanos , Biomarcadores/líquido cefalorraquidiano , Terapia Genética/métodos , Interleucina-8/líquido cefalorraquidiano , Atrofia Muscular Espinal/induzido quimicamente , Atrofia Muscular Espinal/tratamento farmacológico , Atrofia Muscular Espinal/genética , Oligonucleotídeos/uso terapêutico , Oligonucleotídeos Antissenso/uso terapêuticoRESUMO
OBJECTIVES: This study aimed to evaluate the potential budget impact of nusinersen in the treatment of spinal muscular atrophy (SMA) from the perspective of the basic medical insurance payer in China. METHODS: A budget impact analysis model was developed according to ISPOR budget impact analysis guidelines; we integrated health resource consumption, epidemiology, and market data for the treatment of patients with SMA in China, to estimate the impact of nusinersen on basic medical insurance. The microcosting method was conducted to evaluate the treatment cost. One-way sensitivity analysis was performed to explore the stability of the results. RESULTS: If nusinersen could be reimbursed, the impact on the medical insurance funds in the next 1 to 3 years will be 253 million, 333 million, and 426 million, respectively. In addition, it can reduce 0.73 million, 2.17 million, and 2.22 million in complication costs, respectively. CONCLUSIONS: SMA is a rare disease with a very low prevalence; reimbursement of nusinersen will lead to a limited impact on the basic medical insurance and improve the accessibility of treatment.
Assuntos
Atrofia Muscular Espinal , Humanos , Atrofia Muscular Espinal/induzido quimicamente , Oligonucleotídeos/efeitos adversos , Custos de Cuidados de Saúde , ChinaRESUMO
Background and objectives: Spinal muscular atrophy (SMA) is a neurodegenerative disease that leads to progressive proximal muscle weakness and muscle atrophy. To assess the beneficial and adverse effects of nusinersen, a promising intervention for SMA, we conducted a systematic search and meta-analysis of the published randomized control trials (RCTs) of nusinersen for SMA. Materials and methods: Utilizing the Preferred Reporting for Systematic Review and Meta-Analysis (PRISMA), we searched PubMed, Scopus, Web of Science, Cochrane Central, and Clinicaltrials.gov from inception to 22 July 2021. Results: Three RCTs satisfying the inclusion and exclusion criteria covered 274 patients: 178 patients in the nusinersen group. Our results show a significant risk difference (RD) in the motor milestone response (RD: 0.51; 95% CI: 0.39, 0.62; p < 0.00001) and improvement in the HINE-2 score (RD: 0.26; 95% CI: 0.12, 0.40; p < 0.0003) in the nusinersen group compared to the control group. Moreover, a significant decrease in the risk ratio (RR) for severe adverse events (RR: 0.72; 95% CI: 0.57, 0.92; p = 0.007) and any adverse event leading to treatment discontinuation (RR: 0.40; 95% CI: 0.22, 0.74; p = 0.004) was observed. An insignificant result was found for any adverse effects (RR: 0.93; 95% CI: 0.97, 1.01; p = 0.14) and for serious adverse effects (RR: 0.81; 95% CI: 0.60, 1.07; p = 0.14). Conclusions: This review provides evidence that nusinersen treatment was effective in treatment for infants with SMA and was associated with fewer severe adverse events; however, more RCTs are needed to establish evidence.
Assuntos
Atrofia Muscular Espinal , Oligonucleotídeos , Humanos , Lactente , Atrofia Muscular Espinal/induzido quimicamente , Atrofia Muscular Espinal/tratamento farmacológico , Oligonucleotídeos/efeitos adversos , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do TratamentoRESUMO
Evidence for nusinersen administration in adult 5q spinal muscular atrophy (5q-SMA) patients is scarce and based on real-world observational data. The present systematic review and meta-analysis aimed to explore the efficacy and safety of nusinersen in patients older than 12 years of age with 5q-SMA. We searched MEDLINE, EMBASE, the Cochrane Library, and grey literature through April 2021. Cross-sectional studies, case reports, review articles, and studies with follow-up less than 6 months were excluded. We included 12 records (seven case-series, five cohorts) representing 11 population cohorts and enrolling 428 SMA patients. We observed statistically significant improvements on motor function Hammersmith Functional Motor Scale Expanded (HFMSE) and Revised Upper Limb Module (RULM) scores at the longest follow-up assessments [SMD = 0.17(95% CI 0.01-0.33), SMD = 0.22(95% CI 0.06-0.38), respectively]. HFMSE and RULM significant improvements were also detected at the subgroup analysis during 10 and 14 months. HFMSE and RULM amelioration occurred earlier in patients with SMA type 3 or 4 during short-term analysis (≤ 6 months). 6-min walk tests (6MWT) and pulmonary function tests did not change. Minimal clinically important differences in HFMSE and RULM were observed in 43.3% (95% CI 34.5-52.3) and 38.9% (95% CI 27.7-50.7), respectively. Severe adverse events were reported in 2% (95% CI 0-5.8). Treatment withdrawal rate was 3% (95% CI 0.5-6.6). Despite the low quality of evidence and the unmet need for randomized data to establish the safety and efficacy of nusinersen in adults, our meta-analysis confirms that nusinersen is a valuable treatment option for older patients with longer-disease duration.Trial registration: PROSPERO database CRD42020223109.
Assuntos
Atrofia Muscular Espinal , Atrofias Musculares Espinais da Infância , Adulto , Estudos Transversais , Humanos , Atrofia Muscular Espinal/induzido quimicamente , Atrofia Muscular Espinal/tratamento farmacológico , Oligonucleotídeos/uso terapêuticoRESUMO
Spinal muscular atrophy (SMA) is caused by loss-of-function mutations in the survival of motoneuron gene 1 (SMN1). SMA is characterized by motoneuron death, skeletal muscle denervation and atrophy. Disease severity inversely correlates with copy number of a second gene (SMN2), which harbors a splicing defect that causes the production of inadequate levels of functional SMN protein. Small molecules that modify SMN2 splicing towards increased production of functional SMN significantly ameliorate SMA phenotypes in mouse models of severe SMA. At suboptimal doses, splicing modifiers, such as SMN-C1, have served to generate mice that model milder SMA, referred to as pharmacological SMA mice, which survive into early adulthood. Nerve sprouting at endplates, known as terminal sprouting, is key to normal muscle fiber reinnervation following nerve injury and its promotion might mitigate neuromuscular symptoms in mild SMA. Sprouting has been difficult to study in severe SMA mice due to their short lifespan. Here, we show that pharmacological SMA mice are capable of terminal sprouting following reinnervation that is largely SMN-C1 dose-independent, but that they display a reinnervation delay that is critically SMN-C1 dose-dependent. Data also suggest that SMN-C1 can induce by itself a limited terminal sprouting response in SMA and wild-type normally-innervated endplates.
Assuntos
Músculo Esquelético/inervação , Atrofia Muscular Espinal/fisiopatologia , Junção Neuromuscular/fisiopatologia , Animais , Modelos Animais de Doenças , Humanos , Camundongos , Fibras Musculares Esqueléticas/metabolismo , Fibras Musculares Esqueléticas/patologia , Músculo Esquelético/patologia , Músculo Esquelético/fisiopatologia , Atrofia Muscular Espinal/induzido quimicamente , Atrofia Muscular Espinal/patologia , Regeneração Nervosa , Junção Neuromuscular/patologia , Células de Schwann/patologiaRESUMO
OBJECTIVE: The aim of this study was to evaluate the relationship between antiparkinsonian treatments, especially dopamine agonist (DAs) and the development of postural disorders in patients with Parkinson's disease (PD). METHODS: We performed an exploratory case-control study. Cases were PD patients with camptocormia, Pisa syndrome, or anterocollis. Control subjects were PD patients without postural disorders matched by sex and age. Demographic and clinical data including pharmacologic treatments history were collected retrospectively. Characteristics of cases and control subjects were compared using parametric and nonparametric tests accordingly, and logistic regression models were used to analyze correlations. RESULTS: We included 63 patients with PD and postural disorders and 63 control subjects. Cases were more exposed to DAs (74.60% vs 58.73%, P = 0.05) and amantadine (30.16% vs 7.94%, P < 0.05) than control subjects. Cases showed longer disease duration (7.63 ± 7.83 vs 4.27 ± 3.87 years, P < 0.05), higher Hoehn and Yahr stage (2.83 ± 0.80 vs 2.15 ± 0.73, P < 0.05), higher Movement Disorder Society Unified Parkinson's Disease Rating Scale part III score (29.61 ± 1.39 vs 20.76 ± 10.94, P = 0.05), and more dyslipidemia (28.57% vs 12.70%, P < 0.05) than control subjects, as well as lower prevalence of depression (46.03% vs 28.57%, P < 0.05). We found no clinical predictors for the development of postural disorders after multivariable adjusted regression. CONCLUSIONS: Our results suggest a possible association between the use of DAs and amantadine and the development of postural disorders in PD and suggest potential risk factors including advanced disease and more severe motor symptoms. These results support the need of a cautious use of these medications in patients with advanced disease due to the possibility of increasing the risk-benefit ratio.
Assuntos
Antiparkinsonianos/efeitos adversos , Atrofia Muscular Espinal/induzido quimicamente , Pescoço/fisiopatologia , Doença de Parkinson/tratamento farmacológico , Postura , Curvaturas da Coluna Vertebral/induzido quimicamente , Idoso , Idoso de 80 Anos ou mais , Estudos de Casos e Controles , Distribuição de Qui-Quadrado , Avaliação da Deficiência , Feminino , Humanos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Doença de Parkinson/complicações , Postura/fisiologia , Índice de Gravidade de Doença , Estatísticas não Paramétricas , Tronco/fisiopatologiaRESUMO
Camptocormia, a condition that involves the abnormal flexion of the trunk and results in a forward-bending posture, is relatively common during the course of Parkinson disease (PD). Despite this, there is ongoing controversy concerning its mechanisms and no consensus regarding the underlying etiology. This report demonstrates a case in which a dopaminergic agonist (DA) was implicated in the onset of camptocormia episodes in a non-PD patient who developed camptocormia after the start of DA treatment. Over a course of 8 years, the patient experienced intermittent camptocormia, which resulted in multiple falls. After cessation of the DA, the patient showed decreased camptocormia symptoms. This case report suggests that clinicians should consider the possibility of DA-induced camptocormia in patients with PD and non-PD patients receiving DA treatments, and serves to caution clinicians regarding the administration of DAs.
Assuntos
Agonistas de Dopamina/efeitos adversos , Indóis/efeitos adversos , Atrofia Muscular Espinal/induzido quimicamente , Curvaturas da Coluna Vertebral/induzido quimicamente , Idoso , Idoso de 80 Anos ou mais , Agonistas de Dopamina/uso terapêutico , Proteínas da Membrana Plasmática de Transporte de Dopamina/metabolismo , Feminino , Humanos , Indóis/uso terapêutico , Atrofia Muscular Espinal/metabolismo , Curvaturas da Coluna Vertebral/metabolismo , Tremor/tratamento farmacológicoRESUMO
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a devastating disease leading to death within 3-5 years in most cases. New approaches to treating this disease are needed. Here, we report a successful therapy. CASE REPORT: In a 49-year-old male patient suffering from muscle weakness and fasciculations, progressive muscular atrophy, a variant of ALS, was diagnosed after extensive examinations ruling out other diseases. Due to supposed mercury exposure from residual amalgam, the patient's teeth were restored. Then, the patient received sodium 2,3-dimercaptopropanesulfate (DMPS; overall 86 × 250 mg in 3 years) in combination with α-lipoic acid and followed by selenium. In addition, he took vitamins and micronutrients and kept a vegetarian diet. The excretion of metals was monitored in the urine. The success of the therapy was followed by scoring muscle weakness and fasciculations and finally by electromyography (EMG) of the affected muscles. First improvements occurred after the dental restorations. Two months after starting therapy with DMPS, the mercury level in the urine was increased (248.4 µg/g creatinine). After 1.5 years, EMG confirmed the absence of typical signs of ALS. In the course of 3 years, the patient recovered completely. CONCLUSIONS: The therapy described here is a promising approach to treating some kinds of motor neuron disease and merits further evaluation in rigorous trials.
Assuntos
Esclerose Lateral Amiotrófica/induzido quimicamente , Esclerose Lateral Amiotrófica/terapia , Amálgama Dentário/química , Mercúrio , Esclerose Lateral Amiotrófica/tratamento farmacológico , Restauração Dentária Permanente , Exposição Ambiental , Humanos , Masculino , Mercúrio/urina , Pessoa de Meia-Idade , Atrofia Muscular Espinal/induzido quimicamente , Atrofia Muscular Espinal/tratamento farmacológico , Atrofia Muscular Espinal/terapia , Selênio/administração & dosagem , Ácido Tióctico/administração & dosagem , Resultado do Tratamento , Unitiol/administração & dosagemRESUMO
The escalating demand for fipronil by the increasing insects' resistance to synthetic pyrethroids placed a burden on aquatic vertebrates. Although awareness regarding the toxicity of fipronil to fish is arising, the integral alteration caused by fipronil remains unexplored. Here, we investigated on the development toxicity of fipronil and the metabolic physiology perturbation at 120h post fertilization through GC-MS metabolomics on zebrafish embryo. We observed that fipronil dose-dependently induced malformations including uninflated swim bladder and bent spine. Further, the "omic" technique hit 26 differential metabolites after exposure to fipronil and five significant signaling pathways. We speculated that changes in primary bile acid synthesis pathway and the content of saturated fatty acid in the chemical-related group indicated the liver toxicity. Pathway of Aminoacyl-tRNA biosynthesis changed by fipronil may relate to the macromolecular synthesis. Concurrently, methane metabolism pathway was also identified while the role in zebrafish needs further determination. Overall, this study revealed several new signaling pathways in fipronil-treated zebrafish embryo/larval.
Assuntos
Embrião não Mamífero/efeitos dos fármacos , Metaboloma/efeitos dos fármacos , Pirazóis/toxicidade , Poluentes Químicos da Água/toxicidade , Peixe-Zebra/metabolismo , Sacos Aéreos/anormalidades , Sacos Aéreos/efeitos dos fármacos , Sacos Aéreos/embriologia , Animais , Relação Dose-Resposta a Droga , Embrião não Mamífero/anormalidades , Embrião não Mamífero/metabolismo , Cromatografia Gasosa-Espectrometria de Massas , Larva , Metabolômica , Atrofia Muscular Espinal/induzido quimicamente , Atrofia Muscular Espinal/embriologia , Curvaturas da Coluna Vertebral/induzido quimicamente , Curvaturas da Coluna Vertebral/embriologia , Peixe-Zebra/embriologiaAssuntos
Antipsicóticos/efeitos adversos , Benzodiazepinas/efeitos adversos , Atrofia Muscular Espinal/induzido quimicamente , Atrofia Muscular Espinal/diagnóstico , Curvaturas da Coluna Vertebral/induzido quimicamente , Curvaturas da Coluna Vertebral/diagnóstico , Adulto , Humanos , Masculino , Olanzapina , Esquizofrenia Paranoide/diagnóstico , Esquizofrenia Paranoide/tratamento farmacológicoRESUMO
In recent years, the management of Parkinson's disease (PD) has come a long way, leading to an increase in therapeutic options that now include oral and transdermal drug delivery, infusion as well as surgical treatments. Nonetheless, in the evolution of this complex neurodegenerative disorder, several symptoms remain refractory to dopaminergic therapy. It is our aim to review the literature to date and to bring them into focus, as well as emphasizing on pathophysiological mechanisms, profile of risk factors in their development, and therapeutic options. We will focus on freezing of gait, camptocormia, dysphagia and dysphonia, as well as cognitive impairment and dementia because they represent the far end of therapy-resistant symptoms, encompassing poor health-related quality of life and often a more reserved prognosis with either a rapid evolution of the disease, and/or merely a more severe clinical picture. Pathophysiological mechanisms and brain neurotransmitter abnormalities behind these symptoms seem to overlap to some extent, and a better understanding of these correlations is desirable. We believe that further research is paramount to expand our knowledge of the dopamine-resistant symptoms and, consequently, to develop specific therapeutic strategies.
Assuntos
Antiparasitários/efeitos adversos , Resistência a Medicamentos/fisiologia , Doença de Parkinson/tratamento farmacológico , Doença de Parkinson/fisiopatologia , Transtornos Cognitivos/induzido quimicamente , Transtornos de Deglutição/induzido quimicamente , Disfonia/induzido quimicamente , Transtornos Neurológicos da Marcha/induzido quimicamente , Humanos , Atrofia Muscular Espinal/induzido quimicamente , Transtornos de Sensação/induzido quimicamente , Curvaturas da Coluna Vertebral/induzido quimicamenteAssuntos
Inibidores da Captação Adrenérgica/efeitos adversos , Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico , Atrofia Muscular Espinal/induzido quimicamente , Propilaminas/efeitos adversos , Curvaturas da Coluna Vertebral/induzido quimicamente , Inibidores da Captação Adrenérgica/uso terapêutico , Cloridrato de Atomoxetina , Criança , Seguimentos , Humanos , Masculino , Propilaminas/uso terapêuticoAssuntos
Adenina/análogos & derivados , Desoxicitidina/análogos & derivados , Lipodistrofia/induzido quimicamente , Músculo Esquelético/efeitos dos fármacos , Atrofia Muscular Espinal/induzido quimicamente , Nitrilas/efeitos adversos , Organofosfonatos/efeitos adversos , Pirimidinas/efeitos adversos , Adenina/efeitos adversos , Adenina/uso terapêutico , Desoxicitidina/efeitos adversos , Desoxicitidina/uso terapêutico , Combinação de Medicamentos , Emtricitabina , Histocitoquímica , Humanos , Lipodistrofia/complicações , Lipodistrofia/patologia , Masculino , Microscopia , Pessoa de Meia-Idade , Músculo Esquelético/patologia , Atrofia Muscular Espinal/complicações , Atrofia Muscular Espinal/patologia , Nitrilas/uso terapêutico , Organofosfonatos/uso terapêutico , Pirimidinas/uso terapêutico , Rilpivirina , TenofovirAssuntos
Antipsicóticos/efeitos adversos , Distonia/induzido quimicamente , Atrofia Muscular Espinal/induzido quimicamente , Curvaturas da Coluna Vertebral/induzido quimicamente , Adulto , Antipsicóticos/uso terapêutico , Deficiências do Desenvolvimento/tratamento farmacológico , Feminino , Humanos , Masculino , Postura , SíndromeRESUMO
Las enfermedades neuromusculares como la distrofia miotónica (o enfermedad de Steinert) y la atrofia muscular espinal se asocian con las complicaciones perioperatorias relacionadas con la debilidad muscular. Estos pacientes presentan una hipersensibilidad a los bloqueantes neuromusculares no despolarizantes que podría derivar en curarización residual postoperatoria con complicaciones respiratorias. Para evitarlo conviene antagonizar satisfactoriamente el bloqueo neuromuscular (BNM). Sugammadex es el primer relajante selectivo y antagoniza los bloqueos neuromusculares por rocuronio y vecuronio. Se notifican dos casos donde los pacientes recibieron sugammadex para antagonizar un bloqueo neuromuscular provocado por rocuronio. El antagonismo de los BNM por rocuronio en ambos casos fue rápido, eficaz y sin recurarización, no se observaron preocupaciones de seguridad(AU)
Neuromuscular disorders like myotonic dystrophy (dystrophia myotonica or Steinert's disease) and spinal muscular atrophy are associated with perioperative complications related to muscle weakness. These patients have an increased sensitivity to non-depolarising neuromuscular blocking agents, which can lead to postoperative residual curarization (PORC) and its associated respiratory complications. Adequate reversal of neuromuscular blockade is essential to prevent this. Sugammadex is the first selective relaxant binding agent and it reverses rocuronium- and vecuronium-induced neuromuscular block. Two cases are reported in which the patients received sugammadex to reverse a rocuronium-induced neuromuscular block. Reversal of the rocuronium-induced neuromuscular block (NMB) in both cases was fast, effective and without recurarization, and no safety concerns were observed(AU)
Assuntos
Humanos , Masculino , Feminino , Bloqueio Neuromuscular/efeitos adversos , Bloqueio Neuromuscular/métodos , Bloqueadores Neuromusculares/administração & dosagem , Bloqueadores Neuromusculares/efeitos adversos , Bloqueadores Neuromusculares/antagonistas & inibidores , Atrofia Muscular Espinal/induzido quimicamente , Atrofia Muscular Espinal/complicações , Atrofia Muscular Espinal/diagnóstico , Distrofias Musculares/induzido quimicamente , Distrofias Musculares/complicações , Distrofia Miotônica/induzido quimicamente , Distrofia Miotônica/complicações , Distrofia Miotônica/diagnóstico , Doenças Neuromusculares/induzido quimicamente , Doenças Neuromusculares/complicaçõesAssuntos
Antiparkinsonianos/efeitos adversos , Benzotiazóis/efeitos adversos , Atrofia Muscular Espinal/induzido quimicamente , Atrofia Muscular Espinal/diagnóstico , Transtornos Parkinsonianos/diagnóstico , Transtornos Parkinsonianos/tratamento farmacológico , Curvaturas da Coluna Vertebral/induzido quimicamente , Curvaturas da Coluna Vertebral/diagnóstico , Idoso , Erros de Diagnóstico , Feminino , Humanos , Pramipexol , Doenças Vasculares/diagnóstico , Doenças Vasculares/tratamento farmacológicoRESUMO
STUDY DESIGN: Male rats with complete transections of the spinal cord were administered vehicle or methylprednisolone (MP) for 24 h, with or without infusion, for 7 days, of testosterone at either a replacement or low pharmacological doses. Muscles were collected at 7 days after SCI. OBJECTIVE: The objective of this study is to determine, in a rat model of complete spinal cord transection, whether testosterone reduces muscle atrophy or upregulates muscle atrophy-linked genes, induced by 24 h of MP administration at doses comparable to those prescribed in man during the period immediately following acute spinal cord injury (SCI) in an attempt to preserve neurological function. RESULTS: MP significantly reduced the mass of triceps, soleus and plantaris, and significantly increased expression of genes that promote atrophy. Testosterone significantly reduced muscle atrophy induced by MP, but did not prevent it; there was no difference between low- or high-dose testosterone in reducing MP-induced muscle loss. High-dose testosterone reduced expression of muscle atrophy genes more than did low dose. Testosterone-induced declines in mRNA levels for these atrophy-associated genes did not correlate well with protection against MP-induced muscle atrophy. CONCLUSIONS: MP induces marked and lasting changes in the biology of muscle that persisted for at least 7 days, or 6 days after MP has been eliminated from the body. Testosterone partially protected against muscle atrophy and gene expression changes caused by 1 day of MP.